Solutions

Built by the people we built it for.

Qor was built by scientists, investors and consultants, for everyone that needs to get the science right.
Biotech

Board-ready answers, without the headcount.

Qor was founded to serve biotech: where your asset stands, who might partner with you, and who is funding work like yours.
Image
Preclinical founders
The coverage of a BD function, without the BD team
Clinical stage CEOs
Walking into every board meeting with competitor moves already tracked.
Multi-asset teams
Holding a position on every programme, not just the lead one.

Core workflows

  • Your competitive position, kept current
  • Investor identification, and current market evidence for the raise
  • Partnering: who fits, and what comparable deals went for
  • Board-ready briefings, cited to the source
  • Plugs into the tools your team already runs
Management Consultancies

Your method, delivered as an always-on advisory.

Your methodology, running on every market in your book, and it does not stop when the
engagement does. When a market moves, Qor tells you which client it hits, why it matters to them, and that you are the one calling.

Image
Win more clients at speed
Pitch with the market already read, so proposals go out faster.
Evidence-backed answers
Every fact traced to a source, and the reasoning behind each conclusion shown.
Positions that stay live
Your position on a client's market stays current after the project closes.
Re-engagement opportunities
Qor flags the market moves that give you a reason to re-engage a past client.

When a client's world moves

  • Flag it to the client: a short note before they hear it elsewhere, drafted
  • Pull the supporting read: the competitive analysis to back it, drafted
  • Frame the engagement: a one-page proposal outline, drafted
  • Brief the relationship partner who owns the account, drafted
Investors

Every asset in the portfolio, continuously understood.

For VCs, investment banks, and mission-driven funds making billion-dollar calls on specialist assets. Your analysts lose a day a week reading the wire, and the events that move a thesis still slip through. Qor reads every asset in the portfolio, works out which thesis assumptions an event puts under pressure, and shows you the consequence before the next IC.
Image
An interpreted portfolio
Log in to an already-interpreted portfolio, not just a list of assets.
Consulting grade, continuous
The intelligence of a six-figure consulting brief, maintained continuously.
IC-pitch ready, in hours
Every claim traced to source. A full analyst team’s coverage, without the bench.
Proven foundations

Qor is built on BenevolentAI.

For more than a decade, BenevolentAI has developed and applied AI to complex scientific evidence and consequential decisions in life sciences.

Qor brings together that accumulated capability in scientific knowledge, evidence infrastructure, reasoning methods, machine learning, evaluation and domain expertise.

0+ years
Applying AI to life sciences
0+ patents
Across technology, methods and biology

Peer-reviewed research

Across AI, biomedical knowledge and drug discovery

What customers tell us

"Qor has been helping plan near-future business development strategies, specifically by correlating information with the recent activities of investors and collaboration partners."

Dr. Mario Kuttke
Dr. Mario Kuttke
Head of Cell Therapy
Invios

"Competitor phase changes and programme discontinuations reach me without my going to look, which is the part I always used to miss."

Chief Executive
Single-asset biotech spinout

"Most solutions hand you a long text report; this presents it in a way you can actually trust and act on."

Director of Discovery
Metabolic disease biotech

"If I have a target asset of interest I can go in and run it myself. I do not need to raise a ticket with anyone's team and wait."

CI lead
R&D technologies, top-5 global pharma

"Exhaustive is the right default for us. We would rather filter down from everything than discover later that the analyst stopped at the obvious twenty."

Partner
Life sciences strategy consultancy

"It let us cover every autoimmune indication rather than the fifty that seemed closest. Going into a client conversation with that breadth behind you changes the conversation."

Partner
Global commercial and pricing consultancy

"As a non-executive director across several portfolio companies, I need to know what changed and what it means on assets I did not personally diligence. The high-impact digest does that. "

Non-Executive Director
Cell therapy portfolio company

    Tell us what you are trying to stay on top of, and watch Qor work on it live.

    Book a 30-minute demo, and we'll build a briefing around a market you cover.
    Book a demo